SKLB-23bb is primarily investigated for its potential as an anticancer agent, specifically targeting tumor cells through inhibition of key signaling pathways involved in cell proliferation and survival. It has shown promising activity in preclinical studies against certain types of solid tumors, particularly by modulating kinase enzymes that drive cancer progression. Its design allows for improved selectivity and potency, which may reduce off-target effects commonly seen with traditional chemotherapeutics. Research is ongoing to evaluate its efficacy, pharmacokinetics, and potential for clinical development in oncology.